Evidence map›Paper›PMID 38264643›Full record

ArticleFrontiers in immunology2023

Skin repair and immunoregulatory effects of myeloid suppressor cells from human cord blood in atopic dermatitis.

Chang-Hyun Kim, Seung-Min Hong, Sueon Kim, Jae Ik Yu, Soo-Hyun Jung, Chul Hwan Bang, Ji Hyun Lee, Tai-Gyu Kim

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chang-Hyun Kim *ViMedier Platform Group, ViGenCell Inc., Seoul, Republic of Korea.
Seung-Min Hong *ViMedier Platform Group, ViGenCell Inc., Seoul, Republic of Korea.
Sueon KimViMedier Platform Group, ViGenCell Inc., Seoul, Republic of Korea.
Jae Ik YuViMedier Platform Group, ViGenCell Inc., Seoul, Republic of Korea.
Soo-Hyun JungViMedier Platform Group, ViGenCell Inc., Seoul, Republic of Korea.
Chul Hwan BangDepartment of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Ji Hyun LeeDepartment of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Tai-Gyu KimViMedier Platform Group, ViGenCell Inc., Seoul, Republic of Korea.
Catholic University of Korea · KRSeoul St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Previously, we achieved large-scale expansion of bone marrow-derived suppressor cells (MDSCs) derived from cluster of differentiation (CD)34 Methods: Results and discussion: hUCB-MDSCs demonstrated immunosuppressive effects in both human and mouse CD4

Indexed as

Dermatitis, AtopicAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFetal BloodHumansMiceMyeloid Cellsatopic dermatitisinflammatory responsesmyeloid-derived suppressor cellsskin repairT-cells

Identifiers

PMID38264643
PMCPMC10803405
OpenAlexW4390745834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.